Project Grant K08HL183767
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $178K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hershey, PA 17033, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $105,705 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on surfactant protein-A (SP-A) variants and their role in regulating lung innate immunity. The research aims to elucidate molecular mechanisms by which SP-A variants regulate innate immune responses in the lung, with applications to acute and...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,895 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of biological sex and the innate immune response in neonatal bronchopulmonary dysplasia. The award funds research examining how sex chromosomes and X-chromosome inactivation regulate neonatal lung macrophage polarization in response to hyperoxic injury. The project will establish the...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $212,782 on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate developmental dysanapsis in lung development throughout the lifespan in experimental bronchopulmonary dysplasia. The research examines whether intra-amniotic endotoxin causes persistent dysanaptic growth of airways, distal parenchyma, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of The University of Pennsylvania $248,266 on January 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sex chromosomes in neonatal hyperoxic lung injury as a mechanism of bronchopulmonary dysplasia. The recipient will interrogate dosage sensitivity of sex chromosomes and the X-linked gene KDM6A in an early-life hyperoxia mouse model of bronchopulmonary dysplasia. The research...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1,231,094 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the molecular mechanism of pediatric interstitial lung disease caused by surfactant protein C (SFTPC) gene mutations and advance targeted therapies. The University of Pennsylvania research team, led by Dr. Jeremy Katzen, will develop and leverage in vivo mouse models and human induced...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $778,127 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL180797) to enhance lamellar body function via LRRK2 inhibition and reduce respiratory distress syndrome severity in preterm newborns. The research investigates leucine-rich repeat kinase 2 (LRRK2) inhibition as a novel therapeutic approach to enhance endogenous surfactant production in...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $739,313 on September 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study transcriptional regulation of distal lung progenitors in injury and regeneration. The project investigates the role of the transcription factor SOX4 in lung disease, repair, and regeneration using a cross-species comparative approach with human, murine, and ferret models. In human lung...